Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 5
2014 8
2015 16
2016 17
2017 14
2018 13
2019 10
2020 17
2021 25
2022 29
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus.
Scilipoti P, Rosiello G, Larcher A, Fallara G, Cignoli D, Re C, Musso G, Cei F, Tian Z, Karakiewicz PI, Mottrie A, Trevisani F, Raggi D, Necchi A, Bertini R, Salonia A, Briganti A, Montorsi F, Capitanio U. Scilipoti P, et al. Among authors: raggi d. World J Urol. 2024 Apr 27;42(1):264. doi: 10.1007/s00345-024-04976-5. World J Urol. 2024. PMID: 38676733
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Li R, et al. Among authors: raggi d. Eur Urol Oncol. 2024 Jan 5:S2588-9311(23)00296-1. doi: 10.1016/j.euo.2023.12.008. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38184473
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
Pederzoli F, Riba M, Venegoni C, Marandino L, Bandini M, Alchera E, Locatelli I, Raggi D, Giannatempo P, Provero P, Lazarevic D, Moschini M, Lucianò R, Gallina A, Briganti A, Montorsi F, Salonia A, Necchi A, Alfano M. Pederzoli F, et al. Among authors: raggi d. Eur Urol. 2024 May;85(5):417-421. doi: 10.1016/j.eururo.2023.12.014. Epub 2024 Jan 5. Eur Urol. 2024. PMID: 38184414 Free article.
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
Necchi A, Basile G, Gibb EA, Raggi D, Calareso G, de Padua TC, Patanè D, Crupi E, Mercinelli C, Cigliola A, Tateo V, Giannatempo P, Moschini M, Briganti A, Montorsi F, Messina A, Ross JS, Pavlick D, De Cobelli F, Brembilla G. Necchi A, et al. Among authors: raggi d. BJU Int. 2024 Feb;133(2):214-222. doi: 10.1111/bju.16191. Epub 2023 Oct 16. BJU Int. 2024. PMID: 37803523
The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.
Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Msaouel P, Necchi A, Martini A. Robesti D, et al. Among authors: raggi d. BJU Int. 2024 Feb;133(2):158-168. doi: 10.1111/bju.16121. Epub 2023 Jul 25. BJU Int. 2024. PMID: 37422731
124 results